Dextromethorphan-Bupropion Approved

What Is Agitation in Alzheimer's Disease and Why Does It Need Treatment?

Agitation in Alzheimer's disease encompasses excessive motor activity, verbal aggression, and physical aggression that emerges as the disease progresses. The International Psychogeriatric Association consensus criteria define it as observable behavior persistent enough to cause distress to the patient or others. Estimates from longitudinal cohort studies suggest that a majority of patients with Alzheimer's will experience clinically significant agitation at some point in the disease course, with prevalence rising in moderate to severe stages.

Until recently, clinicians had no medications specifically approved for this indication. Off-label use of atypical antipsychotics such as risperidone, olanzapine, and quetiapine was widespread despite FDA black box warnings highlighting increased mortality risk in elderly patients with dementia-related psychosis. The unmet need for a non-antipsychotic option with a more favorable safety profile has been a longstanding priority for geriatric psychiatry.

How Does the Dextromethorphan-Bupropion Combination Work?

Dextromethorphan, long familiar as a cough suppressant, is an uncompetitive NMDA glutamate receptor antagonist with additional activity at sigma-1 receptors and serotonin and norepinephrine transporters. These targets are implicated in the regulation of mood, arousal, and impulsivity. The challenge has been pharmacokinetic: dextromethorphan is rapidly metabolized by the CYP2D6 enzyme, making sustained plasma levels difficult to maintain at standard doses.

By co-formulating dextromethorphan with bupropion, a known CYP2D6 inhibitor, Axsome was able to achieve durable systemic exposure with twice-daily dosing. The combination was first approved by the FDA in 2022 as Auvelity for major depressive disorder. Its development for Alzheimer's agitation followed the ADVANCE clinical trial program, which evaluated the combination against placebo in patients with probable Alzheimer's disease and clinically significant agitation.

What Does This Approval Mean for Patients and Caregivers?

For families and long-term care facilities, agitation is among the most difficult dementia symptoms to manage and a frequent reason patients transition from home to institutional care. A medication specifically indicated and studied for this population may simplify clinical decision-making and reduce the medicolegal complexity of off-label antipsychotic use. Caregivers often describe agitation episodes as more disruptive to quality of life than memory loss itself.

Clinicians will still need to monitor for known adverse effects associated with the combination, including dizziness, somnolence, and potential drug-drug interactions, particularly with serotonergic agents. The drug does not modify the underlying neurodegenerative process and is intended as symptomatic treatment alongside non-pharmacological interventions such as structured environments, caregiver education, and behavioral approaches recommended by Alzheimer's Association guidelines.